



olopatadine hydrochloride 600 micrograms / mometasone furoate monohydrate 25 micrograms per actuation nasal spray (Ryaltris®)

Glenmark Pharmaceuticals Europe Ltd

05 November 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) is accepted for restricted use within NHSScotland.

Indication under review: in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) offers an additional treatment choice of antihistamine and glucocorticoid in a single nasal spray. SMC has previously accepted an alternative antihistamine / glucocorticoid combination for use in allergic rhinitis.

For patients in whom the combination of olopatadine hydrochloride plus mometasone furoate monohydrate is an appropriate choice of therapy, Ryaltris® provides the two ingredients in a single nasal spray.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 29 July 2021.

**Chairman
Scottish Medicines Consortium**